



IGNITING THE EMBERS OF HOPE

SMALL MOLECULE IMMUNOTHERAPIES

ROSE BENGAL MEDICAL SCIENCE

INVESTOR PRESENTATION / Q2 2024

Copyright © 2024 Provectus Biopharmaceuticals, Inc.



FORWARD-LOOKING STATEMENTS

The information in this presentation may include “forward-looking statements” within the meaning of U.S. federal securities legislation and relating to the business of Provectus Biopharmaceuticals, Inc. and its affiliates (Provectus or the Company) that are based on the opinions and estimates of Company management and are subject to a variety of risks, uncertainties, and other factors, which could cause actual events or results to differ materially from those projected in these forward-looking statements.

Forward-looking statements are often, but not always, identified using words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.

The safety, efficacy, and durability of agents and/or uses under investigation by Provectus have not been established. There is no guarantee these agents will receive health authority approval or become commercially available in any country or such agents as products will achieve any revenue levels.


Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on them. Forward-looking statements contained in this presentation are made as of the date hereof or as of the date specifically specified herein.

The Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable federal securities laws. Forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including those described in Item 1A of Provectus’s:

- Annual Report on Form 10-K for the period ended December 31, 2023, and
- Quarterly Report on Form 10-Q for the period ended March 31, 2024.

THE ROSE BENGAL SODIUM (RBS) MOLECULE



EXECUTIVE SUMMARY

Provectus Biopharmaceuticals (OTCQB: PVCT) is a clinical-stage biotechnology company with a bioactive small molecule platform of immunotherapy drug candidates and formulations.




Socioeconomic Benefits of Better Healthcare

Better, accessible, and affordable healthcare can boost lives and productivity, and increase income and GDP, contributing to more robust economies for everyone.

We are confident Provectus's RBS medical science can lead to life-changing advancements in immunotherapy treatments for cancer and many other diseases.

Our commitment lies in alleviating the burden of illness free from undue emotional, financial, and other strains on patients, while ensuring sustained value for Provectus shareholders.

Access to leading healthcare should never hinge on socioeconomic status or geographic location. This principle underscores our profound responsibility to the global public trust we uphold.



EXECUTIVE SUMMARY (continued)



RBS Medical Science

Innovation, versatility, and consistency drive clinical and financial value compared to standard of care medicines. RBS small molecule immunotherapies may have the potential to improve quality of life, resolve disease, enhance survival, and work synergistically with other treatments.



Added Platform Value

RBS medical science also supports clinical-stage immunotherapy drug candidates in dermatology (top.) and ophthalmology (top.); *in vivo* proof-of-concept formulations in oncology and hematology (po.), wound healing (top.), and canine cancers (itu.); and early discovery targets in infectious disease and tissue regeneration & repair.



Injectable Solid Tumor Oncology

Pursuing clinical, regulatory, and commercial milestone achievements for lead intratumoral cancer immunotherapy PV-10 and lead indication metastatic pancreatic cancer. Potential PV-10 treatments target total patient populations of more than \$125+ billion in annual sales.



Company Leadership

The board of directors and management team have diverse and complementary experiences and a strong collective track record of principled culture building, decision-making, and business execution to accomplish Provectus's vision and mission.

OUR UNYIELDING RESOLVE




VISION

Transforming the way the healthcare industry treats disease



MISSION


To innovate safe, effective, accessible, and affordable immunotherapy medicines, while revolutionizing the healthcare industry as we know it



Igniting the Embers of Hope




THE SCIENCE BEHIND RBS



INJECTABLE SOLID TUMOR ONCOLOGY: Mechanisms of Action

RBS MEDICAL SCIENCE: Platform Value Proposition





GO TO MARKET STRATEGY

Provectus: The only source of effectively pure, regulatorily viable, commercially differentiated RBS API

Pharmaceutical Grade RBS:

- ✓ Proprietary, patented, commercially scalable processes of synthesizing the RBS molecule into a viable API
- ✓ Established CMC specifications for API and drug product manufacturing
- ✓ Multi-year stability testing of multiple API and PV-10 drug product lots
- ✓ CMC data review and acceptance by numerous different national drug regulatory agencies¹

Our RBS manufacturing processes employ QbD principles, meet cGMP regulations, and follow ICH guidelines.

Provectus employs process controls to eliminate the formation of historical impurities, avoid the introduction of hazardous impurities in uncontrolled or unreported amounts, and prevent substantial lot-to-lot variability that are all present in non-pharmaceutical grades of rose bengal.

Provectus's Trademark for Our Processes of Synthesizing the RBS Molecule into a Pharmaceutical API

VERIPURE



IMMUNOTHERAPY TREATMENT FOR CANCER

10 MILLION (est.)
People Die Annually from Cancer¹

Provectus is a clinical-stage biotechnology company developing immunotherapy treatments for cancer and many other diseases based on a class of *halogenated xanthene* molecules.

Our flagship molecule is **Rose Bengal Sodium**, which we are testing to treat injectable solid tumor cancers with our lead intratumoral immunotherapy candidate PV-10.

Our network of devoted physician-scientists and researchers at major U.S. and international medical institutions is working tirelessly to bring RBS small molecule immunotherapy treatments to the world.

We invite you to follow our innovation, progress, and growth as we execute on this exciting mission to change lives.





INJECTABLE SOLID TUMOR ONCOLOGY

Lead Indication

- FOLFIRINOX-refractory pancreatic ductal adenocarcinoma metastatic to the liver

mPDAC


- Intratumoral PV-10 + systemic gemcitabine+nab-paclitaxel (GEM-PAC)
- 2nd-line: Versus historical GEM-PAC; est. 7 months median OS¹

18-Patient, Single-Site, Dose Escalation Phase 1 Trial

- Proposed study design aligned with FDA initiative Project Optimus
- 3 dose levels (6 patients each) based on PV-10 tumor fill factor

Endpoints

- Safety and tolerability, PFS (RECIST), OS, and immune correlative markers
- First PET-CT scan (PERCIST) at 24 weeks (6 months) after initial PV-10 treatment



FDA Clearance via Type C Meeting Request

Maximized PV-10 Dosing Regimen May Substantially Improve Patient Outcomes

May Seek AA Based on Phase 1 Trial Results

RBS MEDICAL SCIENCE PLATFORM



	Disease	Administration	Notes
CLINICAL STAGE	Oncology	itu.	PV-10: Stage III and IV melanoma; Cancers of the liver; Lead indication: mPDAC
	Ophthalmology	top.	PV-305: Infectious keratitis ¹
	Dermatology	top.	PH-10: Psoriasis and atopic dermatitis; skin inflammation
IN VIVO PROOF OF CONCEPT	Oncology	po. / itu. pediatric	po.: Adult solid tumor cancers / itu.: Pediatric solid tumors
	Hematology	po.	Pediatric and adult blood cancers, including leukemias
	Wound Healing	top.	Full-thickness cutaneous wounds (e.g., surgical, burn, etc.)
	Animal Health	itu.	Canine soft tissue sarcomas
IN VITRO	Infectious Diseases	tbd	Viruses, bacteria, fungi
	Tissue Regeneration	tbd	

LEADERSHIP TEAM

Ed Pershing, CPA

CEO & Chairman of the Board

- Former CEO and co-founder of Pershing Yoakley & Associates (PYA), top 20 healthcare consulting and top 100 accounting firm in U.S.
- Healthcare experience: turnaround/performance improvement initiatives, long-range planning studies, development of numerous hospital and medical office projects, restructuring of healthcare organizations, liaison between boards of directors and management teams, mergers, acquisitions, divestitures, and leasing arrangements
- Holder of new Provectus patents
- Since 2017

Heather Raines, CPA

CFO

- Previously VP of Finance for BDry Waterproofing, managed financial and accounting functions at AMETEK (NYSE: AME)
- Tax analyst at Goody's Family Clothing; Accounting Manager at Siemens Medical Solutions USA, wholly owned subsidiary of Siemens AG (NYSE: SI), and CTI Molecular Imaging (Nasdaq: CTMI)
- Since 2018

Dominic Rodrigues

President & Vice Chairman of the Board

- Management consulting and corporate development in science & technology-driven industries
- Finance professor at University of Nevada, Las Vegas; Venture capitalist at defense contractor SAIC; Currency derivatives trader at Bank of Montreal; Project manager and engineer at Jacques Whitford
- Holder of new Provectus patents
- Since 2017

Eric Wachter, Ph.D.

CTO

- Co-founder of Photogen Technologies, Provectus's precursor company
- Previously senior research staff member with Oak Ridge National Laboratory (ORNL) conducting research and development of advanced nanosensor and remote sensor technologies in environmental and biomedical sciences as well as for defense and transportation applications
- Holder of more than 40 patents and several research awards
- Since 2002

John Lacey, III, M.D.

Director

- Former Chief Medical Officer and Senior Vice President of University Health System d/b/a University of Tennessee Medical Center (UTMC); operated internal medicine practice for 39 years
- Helped create Knoxville Area Project Access, partnership with Knoxville Academy of Medicine and providers to give primary and specialty health services to uninsured and medically underserved
- Since 2018

Webster Bailey

Director

- Executive Director of Metro Drug Coalition
- 15-year career working in residential addiction treatment center setting
- Winner of multiple awards and accolades for substance abuse prevention initiatives
- Since 2020





OUR COMPETITIVE ADVANTAGE

Open-Source Scientific Research Network

Supporting Proprietary Drug Development



We employ open-source collaboration for basic, applied, and translational medical research, identifying and working with expert physician-researchers and scientists in different disease areas who touch and treat patients every day, cross-sharing molecular biochemical, mechanism, and other knowledge. Our curious, committed, and perseverant network in the U.S. and internationally powers Provectus's drug development endeavors. **This is what sets us apart.**



UNIVERSITY OF CALGARY
CUMMING SCHOOL OF MEDICINE



THE UNIVERSITY OF TENNESSEE
HEALTH SCIENCE CENTER
COLLEGE of MEDICINE



THE ROCKEFELLER UNIVERSITY
Science for the benefit of humanity



THE UNIVERSITY OF TEXAS
MD Anderson
Cancer Center

CAPITAL MARKETS SNAPSHOT

Ticker	PVCT
Exchange	OTCQB
Sector	Biotechnology
Market Cap	\$81.51 million¹
52-Week Range	\$0.056 - \$0.225¹
Shares Outstanding	419.52 million¹

Mailing Address

Provectus Biopharmaceuticals, Inc.
800 S. Gay St., Suite 1610
Knoxville, TN 37929 USA

+1 (866) 594-5999 / Fax: +1 (866) 998-0005

Investor Relations

investorrelations@pvct.com
+1 (866) 594-5999 x1

Media Relations

mediarelations@pvct.com
+1 (866) 594-5999 x4

Transfer Agent

(e.g., stockholder records, transfers, changes of address, etc.)

Broadridge Corporate Issuer Solutions, Inc.,
P.O. Box 1342, Brentwood, NY 11717 USA
shareholder@broadridge.com
+1 (800) 733-1121 / Fax: +1 (215) 553-5402



WHY INVEST IN PROVECTUS



Committed to developing safe, effective, accessible and affordable immunotherapy drugs for those afflicted with cancer and other diseases



Corporate principles of cure, accessibility, accountability, fiscal responsibility, and shareholder value



Clinical trials demonstrating viability of lead cancer immunotherapy candidate PV-10



Open-source network of physician-researchers, scientists, and major medical institutions to alleviate high R&D fixed costs



Highly experienced & passionate management focused on principled culture building, decision-making, and business strategy execution



OTCQB: PVCT

www.ProvectusBio.com

info@provectus.com